RxDoctor Payments DataLook up a doctor →

Troy Bunting, MD

Cardiovascular Disease · Charleston, SCNPI 1558588962

Payments from drug & device makers

$16,013in general payments, 2019–2025

Across 611 payments — averaging $26.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$3K
  • Abbott$2K
  • Medtronic$2K
  • Amgen$813
  • Biotronik Inc.$698
  • Boston Scientific$647
  • plus $6K from 44 others

What the payments were for

  • Travel & lodging$2,43915%
  • Food & beverage$13,43484%
  • Education$690%
  • Entertainment$710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,013 in reported general payments places this provider in the 80th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$439,844
Medicare patients
1,410
Services billed
5,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban361$367,590
EntrestoSacubitril/Valsartan97$124,141
Repatha SureclickEvolocumab117$118,833
XareltoRivaroxaban77$96,771
JardianceEmpagliflozin66$59,561
MounjaroTirzepatide13$13,511
MultaqDronedarone Hcl15$13,111
BrilintaTicagrelor12$11,924
NexletolBempedoic Acid11$4,416
Rosuvastatin Calcium241$4,211
Diltiazem 24hr Er (Cd)Diltiazem Hcl86$3,949
Ranolazine ErRanolazine27$3,641
Metoprolol Succinate255$3,629
Atorvastatin Calcium212$2,943
Ezetimibe92$2,287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$479$367,590361 claims
NovartisEntresto$343$124,14197 claims
Johnson & JohnsonXarelto$256$96,77177 claims
Boehringer IngelheimJardiance$357$59,56166 claims
Sanofi-aventis U.S. LLCMultaq$244$13,11115 claims
AstraZenecaBrilinta$206$11,92412 claims
Esperion Therapeutics, Inc.Nexletol$130$4,41611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →